These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9552377)

  • 1. Chemical inhibitors of cyclin-dependent kinases.
    Meijer L
    Prog Cell Cycle Res; 1995; 1():351-63. PubMed ID: 9552377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
    Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
    Lee HR; Chang TH; Tebalt MJ; Senderowicz AM; Szabo E
    Int J Oncol; 1999 Jul; 15(1):161-6. PubMed ID: 10375610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
    Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
    J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase.
    Soni DV; Jacobberger JW
    Cell Cycle; 2004 Mar; 3(3):349-57. PubMed ID: 14726692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons.
    Park DS; Farinelli SE; Greene LA
    J Biol Chem; 1996 Apr; 271(14):8161-9. PubMed ID: 8626506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
    Zuo MX; Chen XG
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):321-4. PubMed ID: 17892123
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural basis for chemical inhibition of CDK2.
    Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
    Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.
    Ortega MA; Montoya ME; Zarranz B; Jaso A; Aldana I; Leclerc S; Meijer L; Monge A
    Bioorg Med Chem; 2002 Jul; 10(7):2177-84. PubMed ID: 11983514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
    Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
    Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
    Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
    Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
    Lu K; Shih C; Teicher BA
    Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
    Senderowicz AM
    Oncologist; 2002; 7 Suppl 3():12-9. PubMed ID: 12165651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia.
    Sankrithi N; Eskin A
    J Neurochem; 1999 Feb; 72(2):605-13. PubMed ID: 9930732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis.
    Park DS; Morris EJ; Greene LA; Geller HM
    J Neurosci; 1997 Feb; 17(4):1256-70. PubMed ID: 9006970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
    Cory AH; Somerville L; Cory JG
    Anticancer Res; 2005; 25(1A):101-6. PubMed ID: 15816525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.